Tri-and tetraaza-acenaphthylen derivatives as CRF receptor antagonists
US7446108B2 · kind B2 · utility
2Cited by
1References
5Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | May 21, 2002 |
| Grant date | Nov 4, 2008 |
| Priority date | — |
| Expiry date | Jul 29, 2023 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animals, such as stroke. The CRF receptor antagonists of this invention have the following structure:including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, R1, R2, R4, R5, R6, A, X, and Y are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.